Cost-Effectiveness Analysis of Omalizumab for Severe Allergic Asthma in Japan Using Real-World Evidence

Igarashi, Ataru; Kaur, Harneet; Choubey, Abhay; Popli, Akshay; Muthukumar, Madhusubramanian; Yoshisue, Hajime; Funakubo, Minako; Ohta, Ken

doi:10.1016/j.vhri.2021.07.013

Cited by 3 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abnormal decrease in the levels of CD3 + and CD4 + cells indicated compromised immune status. 28,29 CD4 + cells could affect lymphocyte activity, and their reduction affected IgG and IgA levels, compromising the body's ability to fight infections, leading to ineffective asthma control. In this regard, omalizumab, through its mechanism of action, can significantly improve immune functioning in children with allergic asthma.…”

Section: Discussionmentioning

confidence: 99%

“…In this regard, omalizumab, through its mechanism of action, can significantly improve immune functioning in children with allergic asthma. [27][28][29][30] C-ACT scores represent a key assessment tool for evaluating allergic asthma control. Higher C-ACT scores observed in the experimental group indicated more favorable disease control in allergic asthma children.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of omalizumab combined with budesonide formoterol on clinical efficacy, pulmonary function, immune function, and adverse reactions in children with moderate and severe allergic asthma

Chen

Liang

Chu

et al. 2023

Allergol Immunopathol

View full text Add to dashboard Cite

Objective: To evaluate the clinical efficacy and safety of combining omalizumab with budesonide formoterol to treat children with moderate and severe allergic asthma, and investigate the effect of this combination therapy on pulmonary and immune functions. Methods: The data of 88 children with moderate and severe allergic asthma, who were admitted to our hospital between July 2021 and July 2022, were included in the study. The patients were randomly assigned either to control group (n = 44; received budesonide formoterol inhalation therapy) or experimental group (n = 44; received omalizumab subcutaneous injection + budesonide formoterol inhalation therapy) using computer-generated randomization. The clinical efficacy, asthma control (measured using childhood Asthma-Control Test [C-ACT] score), pulmonary function (forced expiratory volume in 1 s, forced vital capacity, and peak expiratory flow), immune function (cluster of differentiation 3 cells [CD3+ cells], cluster of differentiation 4 cells [CD4+ cells], immunoglobulin G, immunoglobulin A, and immunoglobulin E), and adverse reactions were observed and compared between both groups. Results: After treatment, the experimental group had improved levels of pulmonary function and immune function indexes, higher C-ACT scores, and a higher overall response rate than the control group (P < 0.05). In addition, the incidence of adverse reactions was not significantly different between both groups (P > 0.05). Conclusion: The combination of omalizumab with budesonide formoterol for treating moderate and severe allergic asthma in children demonstrated promising clinical efficacy and improved their pulmonary and immune functions, leading to more rational asthma control. The combined regimen demonstrated satisfactory clinical safety and deserved clinical promotion.

show abstract

Section: Discussionmentioning

confidence: 99%